Introduction and effects of structured drug counselling in the hospital

ISRCTN	ISRCTN04371570
DOI	https://doi.org/10.1186/ISRCTN04371570
Protocol serial number	N/A
Sponsor	VU University Medical Center (The Netherlands)
Funders	Agis Health Insurance Company (Agis-zorgverzekering) (The Netherlands), Dutch Association of Medical Specialists (Orde van Medisch Specialisten) (The Netherlands)

Submission date: 28/12/2006
Registration date: 28/12/2006
Last edited: 20/02/2007

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr F A G Hout
Scientific

VU Medical Center
Department of Public and Occupational Health/EMGO Institute
Van der Boechorststraat 7
Amsterdam
1081 BT
Netherlands

Phone	+31 (0)20 444 9682
Email	e.hout@vumc.nl

Study information

Primary study design	Interventional
Study design	Non-randomised, controlled, parallel group trial
Secondary study design	Non randomised controlled trial
Scientific title
Study objectives	The intervention will lead to: 1. More knowledge about (the use of) prescibed medicines 2. A better use of medicines during the stay in the hospital and after discharge
Ethics approval(s)	Approval received from the Medical Ethics Review Committee, VU University Medical Centre Amsterdam on the 25th January 2007.
Health condition(s) or problem(s) studied	Cancer, Lung disease
Intervention	1. Personalised computer generated medication reminder charts during admission and discharge and brochures about specific medicines 2. Patient safety chart with instructions for safe and correct use of medicines The intervention measurements at the departments of lung diseases and oncology lasts three months. The control measurements last three months (same departments).
Intervention type	Other
Primary outcome measure(s)	1. Difference in knowledge about prescribed medicines between intervention and control group at measurement II, per patient corrected for the basis at measurement I (method: questionnaires) 2. Differences in correct use of medicines between intervention and control group at measurement III (method: questionnaires)
Key secondary outcome measure(s)	1. Differences in spotting and reporting medication deviations during the distribution of medicines in hospital between intervention and control group (measurement II) 2. Differences in satisfaction about the received information about medicines (measurement II)
Completion date	01/06/2007

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Not Specified
Target sample size at registration	240
Key inclusion criteria	1. Admission at one of the participating departments 2. Informed consent 3. Duration of admission at least three days maximally a month
Key exclusion criteria	1. Patients younger than 18 years 2. Patients who are emotionally or physically not capable to participate 3. Senile dementia, confusion of the patient 4. Inability to express in Dutch language
Date of first enrolment	02/10/2006
Date of final enrolment	01/06/2007

Locations

Countries of recruitment

Netherlands

Study participating centre

VU Medical Center

Amsterdam
1081 BT
Netherlands

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan